3.07
price down icon2.85%   -0.09
 
loading
Precedente Chiudi:
$3.16
Aprire:
$3.16
Volume 24 ore:
154.70K
Relative Volume:
0.34
Capitalizzazione di mercato:
$69.58M
Reddito:
$66.58M
Utile/perdita netta:
$-19.95M
Rapporto P/E:
-3.3377
EPS:
-0.9198
Flusso di cassa netto:
$-14.27M
1 W Prestazione:
-6.69%
1M Prestazione:
-6.40%
6M Prestazione:
-68.48%
1 anno Prestazione:
-8.36%
Intervallo 1D:
Value
$3.02
$3.20
Intervallo di 1 settimana:
Value
$2.91
$3.787
Portata 52W:
Value
$2.91
$12.23

Exagen Inc Stock (XGN) Company Profile

Name
Nome
Exagen Inc
Name
Telefono
(760) 560-1501
Name
Indirizzo
1261 LIBERTY WAY, VISTA, CA
Name
Dipendente
209
Name
Cinguettio
@ExagenInc
Name
Prossima data di guadagno
2026-03-10
Name
Ultimi documenti SEC
Name
XGN's Discussions on Twitter

Compare XGN vs TMO, DHR, IDXX, A, WAT

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Diagnostics & Research icon
XGN
Exagen Inc
3.07 69.58M 66.58M -19.95M -14.27M -0.9198
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
464.37 172.51B 44.56B 6.72B 6.29B 17.74
Diagnostics & Research icon
DHR
Danaher Corp
187.32 132.46B 24.57B 3.60B 5.26B 5.051
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
573.82 45.69B 4.30B 1.06B 1.04B 13.08
Diagnostics & Research icon
A
Agilent Technologies Inc
111.51 31.51B 7.07B 1.29B 993.00M 4.5355
Diagnostics & Research icon
WAT
Waters Corp
286.57 28.11B 3.17B 642.63M 516.49M 10.77

Exagen Inc Stock (XGN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-09-11 Iniziato B. Riley Securities Buy
2025-07-30 Aggiornamento KeyBanc Capital Markets Sector Weight → Overweight
2025-07-23 Iniziato Craig Hallum Buy
2022-08-05 Downgrade KeyBanc Capital Markets Overweight → Sector Weight
2021-10-15 Ripresa Cowen Outperform
2021-04-15 Iniziato Canaccord Genuity Buy
2020-11-10 Iniziato KeyBanc Capital Markets Overweight
2020-10-08 Iniziato BTIG Research Buy
2020-06-02 Ripresa Cantor Fitzgerald Overweight
2019-10-14 Iniziato Cantor Fitzgerald Overweight
2019-10-14 Iniziato Cowen Outperform
2019-10-14 Iniziato William Blair Outperform
Mostra tutto

Exagen Inc Borsa (XGN) Ultime notizie

pulisher
Mar 14, 2026

Exagen Inc Stock (ISIN: US30063K1051) Faces Headwinds After 2025 Revenue Beat and Cautious 2026 Outl - AD HOC NEWS

Mar 14, 2026
pulisher
Mar 11, 2026

Exagen stock price target lowered to $10 by Canaccord on margin outlook - Investing.com UK

Mar 11, 2026
pulisher
Mar 11, 2026

KeyBanc cuts Exagen stock price target on pricing headwinds - Investing.com Nigeria

Mar 11, 2026
pulisher
Mar 11, 2026

Exagen (XGN): Canaccord Genuity Lowers Price Target to $10.00 | - GuruFocus

Mar 11, 2026
pulisher
Mar 11, 2026

Canaccord Genuity Group Issues Pessimistic Forecast for Exagen (NASDAQ:XGN) Stock Price - MarketBeat

Mar 11, 2026
pulisher
Mar 11, 2026

Exagen Inc. 2025 Annual Report: Innovative AVISE® Autoimmune Disease Testing, Business Strategy, Pipeline, and Intellectual Property Overview - Minichart

Mar 11, 2026
pulisher
Mar 11, 2026

Analyst John Wilkin Lowers Price Target for Exagen (XGN) | XGN S - GuruFocus

Mar 11, 2026
pulisher
Mar 11, 2026

KeyBanc cuts Exagen stock price target on pricing headwinds By Investing.com - Investing.com India

Mar 11, 2026
pulisher
Mar 11, 2026

Exagen (NASDAQ:XGN) Price Target Cut to $10.00 by Analysts at Craig Hallum - MarketBeat

Mar 11, 2026
pulisher
Mar 11, 2026

XGN: Keybanc Lowers Price Target to $10, Maintains Overweight Ra - GuruFocus

Mar 11, 2026
pulisher
Mar 11, 2026

KeyCorp Issues Pessimistic Forecast for Exagen (NASDAQ:XGN) Stock Price - MarketBeat

Mar 11, 2026
pulisher
Mar 11, 2026

Exagen Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:XGN) 2026-03-11 - Seeking Alpha

Mar 11, 2026
pulisher
Mar 11, 2026

Exagen stock price target lowered to $10 by Canaccord on margin outlook By Investing.com - Investing.com Canada

Mar 11, 2026
pulisher
Mar 11, 2026

Exagen outlines $70M–$73M 2026 revenue target while expanding sales force and innovation cadence - MSN

Mar 11, 2026
pulisher
Mar 10, 2026

BTIG cuts Exagen stock price target to $9 on lower revenue outlook By Investing.com - Investing.com India

Mar 10, 2026
pulisher
Mar 10, 2026

William Blair Maintains Outperform on Exagen Inc. (XGN) March 2026 - Meyka

Mar 10, 2026
pulisher
Mar 10, 2026

BTIG cuts Exagen stock price target to $9 on lower revenue outlook - Investing.com India

Mar 10, 2026
pulisher
Mar 10, 2026

Exagen (XGN) Rating Maintained by BTIG, Price Target Lowered to $9.00 | XGN Stock News - GuruFocus

Mar 10, 2026
pulisher
Mar 10, 2026

Exagen (NASDAQ:XGN) Price Target Lowered to $9.00 at BTIG Research - MarketBeat

Mar 10, 2026
pulisher
Mar 10, 2026

Exagen Inc (XGN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Investments By GuruFocus - Investing.com Canada

Mar 10, 2026
pulisher
Mar 10, 2026

Exagen Inc (XGN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Investments - GuruFocus

Mar 10, 2026
pulisher
Mar 10, 2026

4 Analysts Have This To Say About Exagen - Benzinga

Mar 10, 2026
pulisher
Mar 10, 2026

Exagen stock maintains Outperform rating at William Blair By Investing.com - Investing.com India

Mar 10, 2026
pulisher
Mar 10, 2026

Exagen stock maintains Outperform rating at William Blair - Investing.com Australia

Mar 10, 2026
pulisher
Mar 10, 2026

Exagen Q4 2025 Earnings Call Transcript - MarketBeat

Mar 10, 2026
pulisher
Mar 10, 2026

Exagen Inc. Reports Strong Q4 and Full-Year 2025 Financial Results – Earnings Press Release March 2026 - Minichart

Mar 10, 2026
pulisher
Mar 10, 2026

Exagen Q4 Earnings Call Highlights - Yahoo Finance

Mar 10, 2026
pulisher
Mar 10, 2026

Exagen (XGN) Achieves Record Q4 Revenue, Driven by Test Volume G - GuruFocus

Mar 10, 2026
pulisher
Mar 10, 2026

XGN Forecasts Significant Revenue Growth by 2026 - GuruFocus

Mar 10, 2026
pulisher
Mar 10, 2026

Earnings call transcript: Exagen Inc. misses Q4 2025 earnings expectations - Investing.com Nigeria

Mar 10, 2026
pulisher
Mar 10, 2026

Exagen 2025 10-K: Revenue $66.6M; net loss $(19.95)M - TradingView

Mar 10, 2026
pulisher
Mar 10, 2026

XGN: Record 2025 revenue of $66.6M (+19.7%) with net loss of $20.0M; strong AVISE® CTD growth - TradingView

Mar 10, 2026
pulisher
Mar 10, 2026

Exagen Inc. (NASDAQ:XGN) Reports Record 2025 Revenue and Provides 2026 Outlook - ChartMill

Mar 10, 2026
pulisher
Mar 10, 2026

Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance

Mar 10, 2026
pulisher
Mar 10, 2026

Exagen (NASDAQ:XGN) Releases Quarterly Earnings Results, Hits Estimates - MarketBeat

Mar 10, 2026
pulisher
Mar 10, 2026

EXAGEN DIAGNOSTICS ($XGN) Releases Q4 2025 Earnings - Quiver Quantitative

Mar 10, 2026
pulisher
Mar 10, 2026

Exagen reports record 2025 revenue $66.6M, ASP rises to $441; Q4 revenue $16.6M - TradingView

Mar 10, 2026
pulisher
Mar 10, 2026

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results - The Manila Times

Mar 10, 2026
pulisher
Mar 10, 2026

Exagen Earnings Report: Q4 Overview - Benzinga

Mar 10, 2026
pulisher
Mar 10, 2026

BRIEF-Exagen Inc. Q4 Revenue USD 16.631 Million Vs. IBES Estimate USD 16.6 Million - TradingView

Mar 10, 2026
pulisher
Mar 10, 2026

Autoimmune tests for over 137,000 patients power Exagen's 20% revenue rise - Stock Titan

Mar 10, 2026
pulisher
Mar 09, 2026

Exagen Inc. (XGN) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget

Mar 09, 2026
pulisher
Mar 09, 2026

A Peek at Exagen's Future Earnings - Benzinga

Mar 09, 2026
pulisher
Mar 09, 2026

XGN: B. Riley Securities Lowers Price Target, Maintains Buy Rati - GuruFocus

Mar 09, 2026
pulisher
Mar 07, 2026

Insider Sell: Can Exagen Inc grow without dilutionJuly 2025 PreEarnings & AI Driven Stock Reports - baoquankhu1.vn

Mar 07, 2026
pulisher
Mar 06, 2026

Aug Spikes: How strong is Exagen Inc. stock balance sheetTrade Analysis Summary & AI Enhanced Trade Execution Alerts - Naître et grandir

Mar 06, 2026
pulisher
Mar 06, 2026

Exagen announces resale of up to 1.15M shares - MSN

Mar 06, 2026
pulisher
Mar 06, 2026

Exagen Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView

Mar 06, 2026
pulisher
Mar 05, 2026

Exagen Inc. (NASDAQ:XGN) Receives Average Rating of “Moderate Buy” from Analysts - Defense World

Mar 05, 2026
pulisher
Mar 05, 2026

Exagen Inc. (NASDAQ:XGN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Mar 05, 2026
pulisher
Mar 04, 2026

John Aballi Sells 15,698 Shares of Exagen (NASDAQ:XGN) Stock - MarketBeat

Mar 04, 2026

Exagen Inc Azioni (XGN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
diagnostics_research LH
$263.80
price up icon 0.34%
diagnostics_research DGX
$199.70
price down icon 0.59%
diagnostics_research MTD
$1,173.74
price up icon 0.49%
$187.85
price down icon 1.29%
diagnostics_research IQV
$164.72
price up icon 1.10%
diagnostics_research WAT
$286.57
price up icon 1.15%
Capitalizzazione:     |  Volume (24 ore):